Vivet will be at BIO Europe in Berlin on November 6-8th
Vivet Therapeutics will be at BIO Europe in Berlin on November 6-8th 2017
Vivet presenting at Gene Therapy for Rare Disorders Europe
Vivet Therapeutics will be presenting at Gene Therapy for Rare Disorders Europe on Oct 31-Nov 2, 2017
Vivet will be at AASLD Liver Meeting 2017
Vivet Therapeutics will be at
Vivet at Mkt Access for Cell & Gene Therapies Congress in London
Vivet Therapeutics will be attending the upcoming
Vivet at 25th anniversary ESGCT meeting in Berlin
Vivet Therapeutics will be at the upcoming European Society of Gene And Cell Therapy (ESGCT) annual meeting in Berlin on Oct. 17-20,…
FierceBiotech names Vivet Therapeutics as one of its 2017 “Fierce 15” Biotech Companies.
PARIS, France September 28th, 2017, Vivet Therapeutics is proud to announce that it has been named by FierceBiotech as one of 2017’s
Vivet’s First Gene Therapy Product, VTX 801 for Wilson’s Disease, Receives European and US Orphan Drug Designation
PARIS, France September 26th, 2017, Vivet Therapeutics, announced today that both the Food and Drug Administration (FDA) and the European Commission (EC) have granted Orphan Drug Designation (ODD) for Vivet’s lead gene therapy product
Gene Therapy of Liver Diseases
In Europe, a disease is defined as rare when it affects fewer than one out of every 2,000 people. However, as many as 30 million people may suffer from one of the more than 6,000 existing rare diseases.
EMA News
This section of the website provides information for companies and individuals involved in developing and marketing medicines for human use in the European Union (EU)
FDA news : Cellular & Gene Therapy Guidances
A useful resource of Cellular & Gene Therapy Guidance Documents
